Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-11-08
1998-04-21
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514211, 514212, 514218, 5142278, 514252, 514307, 514311, 514315, 514316, 514318, 514326, 514343, 514365, 514374, 514422, 514423, 540480, 5404813, 540544, 540553, 540575, 5405967, 540602, 540603, 540607, 540610, 544 60, 544129, 544130, 544141, 544360, 544372, 546145, 546146, 546153, 546165, 546187, 546194, 546206, 546207, 546208, 546209, 546210, 546245, 248146, 248212, 2483147, 248517, 248537, 248548, 248572, A61K 31535, A61K 31495, A61K 3154, C07D41312, C07D40312, C07D40112, C07D41712
Patent
active
057417920
ABSTRACT:
Heterocyclic thrombin inhibitors are provided which have the structure ##STR1## wherein n, R, R.sup.1, R.sup.2, R.sup.3, G, G.sub.x, R.sup.6 ', Ra, Xa, R.sup.6, Rb, R.sub.3, p, Q, A and R.sup.4 are as defined herein.
REFERENCES:
patent: 4244865 (1981-01-01), Ali et al.
patent: 4258192 (1981-03-01), Okamoto et al.
patent: 4316889 (1982-02-01), Sandor et al.
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 4904661 (1990-02-01), Pilgrim et al.
patent: 5002964 (1991-03-01), Lascalzo
patent: 5153176 (1992-10-01), Abe et al.
patent: 5518735 (1996-05-01), Sturzebecher
patent: 5561146 (1996-10-01), Kim
Stuerzebecher J, Markwardt F, Walsmann P, Voigt B, Wagner G. Pharmazie 42(2), 114-116, 1987.
Kuznetsov VA, Pozdnev VF, Bol'shakova TD. Lab. Delo, 8, 43-45, 1990.
Poe m, Bennet CD, Biddison WE, Blake JT, Norton GP, Rodkey JA, Sigal NH, Turner RV, Wu, JK, Zweerink HJ. J. Biol. Chem. 263 (26), 13215-22, 1988.
Rubini E, Gilon C, Selinger Z, Chorev M. Tetetrahedron 42(21) 6039-45, 1986.
Robert M. Knabb et al, "In Vivo Characterization of a New Synthetic Thrombin Inhibitor," Thrombosis and Hemostasis (1992) 67, 56-59.
Charles V. Jackson et al, "Pharmacological Assessment of the Antithrombotic Activity of the Peptide Thrombin Inhibitor, D-Methyl-Phenylalanyl-Prolyl-Arginal (GYKI-14766), in a Canine Model of Coronary Artery Thrombosis," J. Pharm. Exp. Ther. (1992) 261, 546-552.
Greissbach, U. et al "Peptide aldehydes as inhibitors of proteolytic enzymes-synthetic aspects" CA102:181323a (1983).
Shuman, R.T. et al "Highly Selective Tripeptide Thrombin Inhibitors" J. Med. Chem. 36, 314-19 (1993).
Bajusz, S. et al "Highly Active and Selective Anticoagulants" J. Med. Chem. 33, 1729-35 (1990).
Rubini, E. et al "synthesis of Isosteric Methylene-oxy Pseudodipeptide Analogues as Novel Amide Bond Surrogate Units" Tetrahedron 42, 6039-45 (1986).
Spatola, A.F. et al "Amide Bond Surrogates: Pseudopeptides and Macrocycles" Tetrahedron 44, 821-833 (1988).
McOmie, J.F.W. Protective Groups in Organic Chemistry Plenum Press, pp. 46, 55-57, 73 (1973).
Banner, D. et al "Serine Proteases: 3D Structures, Mechanisms of Action and Inhibitors" Prospect. Med. Chem. Bernard (Ed), Verlag Publishing, pp. 27-43 (1993).
Hackh's Chemical Dictionary, McGraw-Hill, p. 16 (1982).
Burger, A. "A Guide to the Chemical Basis of Drug Design" Wiley, Science, p. 15 (1984).
Das Jagabandhu
Hall Steven E.
Han Wen-Ching
Kimball Spencer D.
Lau Wan Fang
Bristol--Myers Squibb Company
Huang Evelyn
Ivy C. Warren
Rodney Burton
LandOfFree
Heterocyclic thrombin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic thrombin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic thrombin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057672